Catalin Bobirca/LinkedIn
Jun 16, 2026, 14:36
Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
Catalin Bobirca, Director of Global Medical Affairs Hemoglobinopathies at Novo Nordisk, shared a post on LinkedIn:
“Back from EHA 2026 and feeling incredibly inspired!
The updates in hemoglobinopathies research highlight just how far we’ve come—and where the future of medicine is heading.
Beyond the data, the highlight of my week was connecting (and reconnecting) with so many dedicated physicians and peers.
Thank you for the insightful discussions and your shared commitment to transforming patient lives.
Let’s stay connected!
One special thanks to the team that made all this possible!”
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology